Company News: Abbott and Solvay Pharmaceuticals

Share this article:
Abbott completed its $6.2 billion acquisition of Solvay Pharmaceuticals, and said it expects the acquisition to add about $2.9 billion to 2010 sales, mostly outside the US, and around $500 million to the company's annual R&D investment. “In addition to taking both Abbott and Solvay products into new and expanding markets, the acquisition enhances our R&D investment, providing Abbott with the opportunity to drive future pharmaceutical growth,” said Abbott chairman and CEO Miles White in a statement.
Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.